VIEW
IN BROWSER
EDITOR'S
NOTE: Big4Bio newsletters will not be
published from May 22nd-25th; they will resume
distribution on Tuesday, May 26th.
|
 |
| May
21, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
WEEKLY CEO Q&A:
Sean A. McCarthy, CEO & Chairman,
CytomX Therapeutics |
| In
this Q&A, McCarthy reflects on the
origin of CytomX's differentiated
scientific vision, clinical and strategic
milestones that define the company's
progress, what it takes to sustain a
high-performing team through uncertainty,
and why he remains optimistic about the
future of oncology innovation. More |
|
|
 |
| Biotech’s
most flexible vivarium lab space
to launch and scale studies. |
|
Learn More
→ |
|
|
- Arsenal Medical: Receives FDA IDE Approval
for the RADIANT Pivotal Trial of NeoCast in
Chronic Subdural Hematoma More
- Corbus Pharmaceuticals: Appointment of
Nishant Saxena as Chief Business Officer and
Schedules a Pre-2026 ASCO CRB-701 Data
Conference Call More
- Ernexa Therapeutics: Releases Virtual
Investor KOL Connect Segment Featuring Dr.
Elena Ratner Highlighting Ovarian Cancer
Landscape and ERNA-101 Opportunity More
- Genethon and Ampersand Biomedicines:
Partnership to Design Novel AAV Vectors With
Enhanced Tissue Specificity for More
Effective and Better Tolerated Gene
Therapies More
- Ipsen: National Survey Shows Young People
Are Not Prepared for the Shift From Pediatric
to Adult Healthcare More
- Predicta Biosciences: Appoints Dr. Craig L.
Tendler as Independent Director to Its Board More
- Theromics:
Appoints Andrew C. Zeringue as Chief
Executive Officer More
|
|
 |
Charles
River CFO
Keeping It Steady During a
Company-Defining Moment |
|
Learn More
→ |
|
|
- CVS Chief Snags $21.2M Pay Package With More
Than 90% Tied to Performance
More*
- Dyne Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Hemab Therapeutics: First Quarter 2026
Financial Results More
- Massachusetts Logs Eighth Biotech IPO
Filing This Year — Will the Trend Continue?
More*
- More on Parabilis Seeking IPO to Fund
Phase III for Desmoid Tumour Drug More*
More
More
- More on Takeda Facing $885M Hit After
Landmark Pay-for-Delay Lawsuit Verdict More
- Nanobiotix: Launch of Global Follow-On
Offering More
- Nanobiotix: Temporary Trading Halt of Its
Ordinary Shares on Euronext Paris More
- Relay Therapeutics: Pricing of Public
Offering of Common Stock More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- Directed Evolution of Small RNA-Stabilizing
Motifs That Improve Prime-Editing Efficiency
More
- Radio-pharmaceuticals Are Changing the
Rules of Cancer Therapy More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- The Brain’s Code Seems to Be in Constant
Flux. Neuroscientists Are Baffled More
|
|
- Telling Your Science Story to
Investors More
- AI in Biotech: The New
Frontier for Leadership & Strategy More
- Andrea Pfeifer Ends 23-Year Reign at AC
Immune; Acadia’s Top R&D Exec Announces
Retirement More*
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- From Seed to Series C: What Investors Look
for Beyond the Science More
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
